S TEROID IN INFECTIOUS DISEASES Dr Farhad Abbasi Infectious diseases specialist.

Slides:



Advertisements
Similar presentations
Update on Imaging: Detection of Iron in Liver and Heart Tim St. Pierre, BSc, PhD Professor School of Physics The University of Western Australia Crawley,
Advertisements

Palumbo A et al. Proc ASH 2013;Abstract 536.
Status Epilepticus-Definition
USE OF STEROIDS IN PATIENTS WITH COPD EXACERBATION Richard C. Walls.
Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotype 2 or 3 LONESTAR-2 Phase 2 Treatment Experienced Lawitz E, et.
Palumbo A et al. Proc ASH 2012;Abstract 446.
Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 TURQUOISE-II Phase 3 Treatment.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ADVANCE (Study 108) Phase 3 Treatment Naïve Jacobson IM, et. al. N Engl J Med.
Anti-virals versus vaccination against varicella Vana Papaevangelou,MD Lecturer in Pediatrics Athens Medical School.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
HSV Encephalitis Jack Kuritzky, PGY-2 UNC Internal Medicine August 31, 2009.
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Compensated Cirrhosis
BY MELISSA JAKUBOWSKI PULMONARY DISEASE TREATMENT CONCERNING COPD.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
1 Hepatitis B Treatment Dr R.V.S.N.Sarma., M.D., Consultant Physician & Chest Specialist.
Sarah Struthers, MD March 19, 2015
Hormone Refractory Prostate Cancer A Regulatory Perspective of End Points to Measure Safety and Efficacy of Drugs Hormone Refractory Prostate Cancer Bhupinder.
Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates.
Sepsis and Early Goal Directed Therapy
Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.
Sepsis course – VI: Surviving Sepsis Campaign Zsolt Molnár University of Szeged 2009.
Corticosteroids in adults with bacterial meningitis
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.
INFECTIOUS MONONUCLEOSIS (epstein-barr virus) Professor: Ma lian.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study Phase 3 Treatment-Naïve and Treatment-Experienced Nelson DR,
Infectious mononucleosis
SIRS Dr. Jonathan R. Goodall M62 Coloproctology Course 31 st March 2006.
Respiratory CONNECT meeting Dr Julius Cairn. Risk stratification in PE Clinical parameters – shock, JVP, S3 Imaging – CTPA, echo Biomarkers – Troponin,
HvC Comparative Effectiveness Project Groups 5 and 6
Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.
Treatment Multiple Myeloma. Symptomatic/progressive myeloma: Systemic therapy - to control progression of myeloma Supportive care - to prevent serious.
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.
Efficacy and Comparability of Thiazide-type Diuretics
Bortezomib (VELCADE), Rituximab, Cyclophosphamide, Dexamethasone (VRCD) combination therapy in front-line low-grade non-Hodgkin lymphoma (LG-NHL) is active.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.
Rituximab plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in.
ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Mark TM et al. Proc ASH 2012;Abstract 77.
Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotype 2 or 3 LONESTAR-2 Phase 2 Treatment Experienced Lawitz E, et.
Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.
A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Idelalisib (GS- 1101) in Combination with Rituximab and/or Bendamustine.
Case Discussion CMID Outline Epidemiology Clinical presentation Management: -Investigations -Antimicrobial therapy -Adjunct therapy Complications.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Shah.
Steroid Therapy.
LSU Journal Club Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia A Systematic Review and Meta-analysis Scott Hebert,
Prednisone 3 Times A Day Cheap Deltasone No Prescription prednisone for dogs dose methylprednisolone iv to oral prednisone prednisone and the flu vaccine.
Childhood Infectious Diseases Skimmia Japonica Rubella FAHAD AL ZAMIL Professor & Consultant Pediatric Infectious Diseases King Khalid University Hospital.
Comparison between pathogen directed antibiotic treatment and empiri cal broad spectrum antibiotic treatment in patients with community acquired pneumonia.
“Monitoring Systemic Lupus Erythematosus” Andres Quiceno, MD Presbyterian Hospital of Dallas.
CCO Independent Conference Highlights
Palumbo A et al. Proc ASH 2012;Abstract 200.
ELOQUENT-2: Elotuzumab + Len/Dex in R/R MM
Attal M et al. Proc ASH 2010;Abstract 310.
Mateos MV et al. Proc ASH 2013;Abstract 403.
The IDEAL Study Reference
Elotuzumab, Lenalidomide, and Low-Dose Dexamethasone in Relapsed/Refractory Myeloma Slideset on: Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination.
Steroids in Sepsis.
A CASE CHALLENGE IN HFrEF:
Krop I et al. SABCS 2009;Abstract 5090.
Dr Immaculate Kariuki Consultant Paediatrician Nairobi, Kenya
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
N3-378 Template 12/31/2018 7:52 PM 8 8.
Baselga J et al. SABCS 2009;Abstract 45.
TREATMENT OF THE ACUTE GOUT ATTACK:
Boccadoro M et al. Proc ASCO 2011;Abstract 8020.
New Models of Care in Idiopathic Pulmonary Fibrosis
Presentation transcript:

S TEROID IN INFECTIOUS DISEASES Dr Farhad Abbasi Infectious diseases specialist

S TEROIDS AND I NFECTIONS

Where? When? How much? How long?

B ACTERIAL MENINGITIS Concomitant or before antibiotic therapy Dose: 10 mg stat, 10 mg q6h for 2-4 day Machanism?

Dexamethasone0.15 mg/kg IV q6°x4 days Reduced hearing loss 50 % decrease in mortality Decreased neurologic sequelae No adverse effects de Gras and van de Beek. N EnglJ Med 2002;347:

TUBERCULOUS MENINGITIS Improved patient survival Stage II and III Prednisolone mg/day for 2 weeks with tapering in 4 weeks

S EPTIC S HOCK 50 mg hydrocortisone q6 hours for 5 days No survival benefit We suggestIV hydrocortisone be given ONLY when unresponsive to fluid resuscitation and vasopressortherapy Sprung et al. N EnglJ Med 2008;358(2): Dellinger et al. CritCare Med 2008;36(1):

S TEROIDS IN S EPSIS ? Inconclusive evidence Diverging expert opinion New trials underway…. “Embrace Uncertainty” Jaeschkeand Angus JAMA;301(22):

TUBERCULOUS PERICARDITIS Decreased mortality Prednisolone 60 mg for 4 weeks Prednisolone 30 mg for 4 weeks Prednisolone 15 mg for 2 weeks

TUBERCULOUS PLEURITIS Steroid hasten symptomatic improvement and fluid resorption but no long term benefit has been shown

SEVERE TYPHOID FEVER Significant reduction in mortality Dexamethasone 3 mg/kg IV stat then 8 dose of 1 mg/kg q6h In Pt with altered mental status or shock

I NFECTIOUS MONONUCLEOSIS Steroid indiation: 1. Airway obstruction 2. Hemolytic anemia 3. Aplastic anemia 4. Severe thrombocytopenia 5. CNS involvement 6. Myocarditis/ pericarditis 7. Severe prolong prostration

Prednisolone mg/ day tarared in 1-2 weeks

H ERPES Z OSTER

208 patients Age > 50 years and immunocompetent Rash < 72 hours Acyclovir & Prednisone for 21 days Improved quality of life measures, decreased pain, better sleep, return to normal Whitley et al. Ann Intern Med 1996;125:

Acyclovir 800 mg 5 times a day for 7 –10 days ADD if age > 50 years Prednisone: 30 mg BID days 1 –7 15 mg BID days 8 – mg BID days

P HARYNGITIS & S TEROIDS Meta-analysis 8 Trials: All 8 = earlier reduction in pain (range 5 hours –1 day) No difference in time off work/school No serious adverse events IM steroids no better than PO Korbet al. Ann FamMed 2010:8:58-63

B ELL ’ S P ALSY Herpes Simplex Virus Meta-analysis 18 trials ( 2786 patients ) Antivirals alone - Steroids alone + Antivirals AND steroids +++ deAlmediaet al. JAMA 2009;302:

PCP AND S TEROIDS Pneumocystisjiroveci PaO2< 70 mm Hg Reduces respiratory failure and death Prednislone: 80 mg days mg days mg days 11-21